Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- mechlorethamine
- oxaliplatin
Interactions between your drugs
mechlorethamine oxaliplatin
Applies to: mechlorethamine, oxaliplatin
MONITOR: The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow, gastrointestinal tract and heart.
MANAGEMENT: Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.
References (9)
- (2001) "Product Information. Paraplatin (carboplatin)." Bristol-Myers Squibb
- (2001) "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb
- (2022) "Product Information. Fluorouracil (fluorouracil)." Roche Laboratories
- (2001) "Product Information. Zanosar (streptozocin)." Pharmacia and Upjohn
- (2001) "Product Information. Ellence (epirubicin)." Pharmacia and Upjohn
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid
- Cerner Multum, Inc. "Australian Product Information."
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Chlorambucil
Chlorambucil (Leukeran) is an anti-cancer chemotherapy drug used for treatment of Hodgkin’s disease ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Vinblastine
Vinblastine is used for breast cancer, cancer, choriocarcinoma, histiocytosis, hodgkin's lymphoma ...
Ifosfamide
Ifosfamide is used for cancer, cervical cancer, testicular cancer
Fludarabine
Fludarabine is used for cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia ...
Etoposide
Etoposide is used for cancer, hodgkin's lymphoma, multiple myeloma, ovarian cancer, small cell lung ...
Vincristine
Vincristine is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.